HC Wainwright Issues Optimistic Outlook for FENC Earnings

Adherex Technologies Inc. (NASDAQ:FENC – Free Report) – Equities researchers at HC Wainwright increased their Q3 2027 earnings per share estimates for Adherex Technologies in a research report issued on Wednesday, November 18th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.28 per share for the quarter, up from their prior estimate of $0.25. HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Adherex Technologies’ current full-year earnings is $0.36 per share. HC Wainwright also issued estimates for Adherex Technologies’ Q4 2027 earnings at $0.33 EPS.

FENC has been the subject of several other research reports. Zacks Research upgraded shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 12th. Weiss Ratings raised shares of Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, November 13th. Wedbush raised their price target on shares of Adherex Technologies from $13.00 to $16.00 and gave the stock an “outperform” rating in a report on Wednesday, August 12th. Finally, B. Riley Financial restated a “buy” rating and issued a $19.00 price target (up from $18.00) on shares of Adherex Technologies in a report on Monday, November 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $17.50.

Read Our Latest Research Report on Adherex Technologies

Adherex Technologies Stock Down 2.7%

Shares of FENC stock opened at $13.09 on Thursday. The company has a market cap of $460.99 million, a price-to-earnings ratio of 182.29 and a beta of 1.29. Adherex Technologies has a 52 week low of $5.65 and a 52 week high of $13.85. The firm has a 50 day moving average of $10.79 and a 200-day moving average of $9.50.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.02. The firm had revenue of $19.61 million for the quarter, compared to analyst estimates of $18.87 million. Adherex Technologies had a return on equity of 8.96% and a net margin of 2.52%.

Insider Buying and Selling

In other Adherex Technologies news, insider Pierre Sargis Sayad sold 12,000 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the transaction, the insider owned 9,519 shares in the company, valued at approximately $115,941.42. This represents a 55.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert Andrade sold 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the completion of the sale, the chief financial officer directly owned 217,675 shares of the company’s stock, valued at $2,564,211.50. This trade represents a 25.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is currently owned by corporate insiders.

Key Stories Impacting Adherex Technologies

Here are a few of the latest stories about FENC:

  • Positive Sentiment: HC Wainwright raised its earnings estimates across several periods, including FY2026 EPS to $0.34 from $0.21 and FY2027 EPS to $1.00 from $0.87. It also increased estimates for Q4 2026, Q1 2027 and Q2 2027. The analyst maintained a Buy rating and a $17 price target. Adherex Technologies stock price expected to rise, HC Wainwright analyst says
  • Positive Sentiment: HC Wainwright also lifted its Q3 and Q4 2027 EPS forecasts, adding to the improved earnings outlook. These higher projections may be supportive for FENC, but are analyst estimates and do not guarantee future results. Adherex Technologies analyst estimates

About Adherex Technologies

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

Recommended Stories

Earnings History and Estimates for Adherex Technologies (NASDAQ:FENC)

Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.